Last reviewed · How we verify

Cholic Acids — Competitive Intelligence Brief

Cholic Acids (Cholic Acids) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid replacement therapy. Area: Gastroenterology / Metabolic Disorders.

phase 3 Bile acid replacement therapy Farnesoid X receptor (FXR) and TGR5 signaling pathways Gastroenterology / Metabolic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Cholic Acids (Cholic Acids) — Mirum Pharmaceuticals, Inc.. Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cholic Acids TARGET Cholic Acids Mirum Pharmaceuticals, Inc. phase 3 Bile acid replacement therapy Farnesoid X receptor (FXR) and TGR5 signaling pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid replacement therapy class)

  1. Mirum Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cholic Acids — Competitive Intelligence Brief. https://druglandscape.com/ci/cholic-acids. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: